FDA Delays Decision on Orexigen Obesity Pill by 3 Months

The FDA extended the review of Orexigen Therapeutics' (OREX) obesity pill Contrave by three months. Wednesday's expected approval decision is now pushed back to Sept. 11. 

"The FDA has indicated that the review extension is needed to reach agreement on the post-marketing obligation related to the previously agreed upon evaluation of cardiovascular (CV) outcomes for NB32," Orexigen said, in a statement. NB32 is Contrave. 

While the approval decision delay is a disappointment, it may work in Orexigen's favor if FDA allows cardiovascular outcomes data favorable to Contrave to be included in the weight loss drug's label. Orexigen's competitors Vivus (VVUS) and Arena Pharmaceuticals  (ARNA) lack data ruling out an increased risk of heart-related side effects. 


Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Investing

Delta Air Lines Slips on Lower 2019 Profit Forecast

Delta Air Lines Slips on Lower 2019 Profit Forecast

Jim Cramer Likes UAL - Watch Oil or Wait for Weakness Before Buying

Jim Cramer Likes UAL - Watch Oil or Wait for Weakness Before Buying

Discounted Cash Flow Valuation: Definition, Investing and Stocks

Discounted Cash Flow Valuation: Definition, Investing and Stocks

Starbucks Shares Gain as Investor Day Highlights China Growth Ambitions

Starbucks Shares Gain as Investor Day Highlights China Growth Ambitions

Chart of the Day: There are Better Bargains Out There Besides GE

Chart of the Day: There are Better Bargains Out There Besides GE